The companies are hoping that new data on recently-filed eplontersen will boost the drug's chances of challenging Alnylam’s Amvuttra and Onpattro.
A few weeks after filing eplontersen with regulators in the US, AstraZeneca PLC and Ionis Pharmaceuticals, Inc. have presented positive long-term data for the transthyretin amyloidosis (ATTR) therapy.
At the beginning of March, the companies filed eplontersen with the US Food and Drug Administration for patients with hereditary...
Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.
Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.
Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.
